Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4645112
Max Phase: Preclinical
Molecular Formula: C25H23F2N5O4S
Molecular Weight: 527.55
Molecule Type: Unknown
Associated Items:
ID: ALA4645112
Max Phase: Preclinical
Molecular Formula: C25H23F2N5O4S
Molecular Weight: 527.55
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(CC(=O)Nc4nc5ccc(F)cc5s4)CC3)cc21
Standard InChI: InChI=1S/C25H23F2N5O4S/c1-2-31-12-16(24(35)36)23(34)15-10-17(27)20(11-19(15)31)32-7-5-30(6-8-32)13-22(33)29-25-28-18-4-3-14(26)9-21(18)37-25/h3-4,9-12H,2,5-8,13H2,1H3,(H,35,36)(H,28,29,33)
Standard InChI Key: OGNIYESFLIUZNA-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 527.55 | Molecular Weight (Monoisotopic): 527.1439 | AlogP: 3.37 | #Rotatable Bonds: 6 |
Polar Surface Area: 107.77 | Molecular Species: ACID | HBA: 8 | HBD: 2 |
#RO5 Violations: 1 | HBA (Lipinski): 9 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: 5.61 | CX Basic pKa: 4.44 | CX LogP: 3.49 | CX LogD: 1.75 |
Aromatic Rings: 4 | Heavy Atoms: 37 | QED Weighted: 0.40 | Np Likeness Score: -2.14 |
1. Suaifan GARY, Mohammed AAM.. (2019) Fluoroquinolones structural and medicinal developments (2013-2018): Where are we now?, 27 (14): [PMID:31182257] [10.1016/j.bmc.2019.05.038] |
2. Gao F, Wang P, Yang H, Miao Q, Ma L, Lu G.. (2018) Recent developments of quinolone-based derivatives and their activities against Escherichia coli., 157 [PMID:30193220] [10.1016/j.ejmech.2018.08.095] |
Source(1):